PCRX Stock Overview
Engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PCRX from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Pacira BioSciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.65 |
| 52 Week High | US$35.95 |
| 52 Week Low | US$11.16 |
| Beta | 0.80 |
| 1 Month Change | 16.20% |
| 3 Month Change | 28.43% |
| 1 Year Change | -41.76% |
| 3 Year Change | -67.89% |
| 5 Year Change | -55.21% |
| Change since IPO | 179.91% |
Recent News & Updates
Recent updates
Pacira BioSciences: Not Done Yet Despite Devastating Share Price Losses
Nov 25Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%
Sep 06
Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding
Jul 23These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely
Jun 07Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models
May 10Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult
May 03Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?
Feb 05Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement
Jan 05We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Nov 03Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?
Jul 28Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price
Jul 07Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?
Apr 18We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt
Dec 28Assessing Pacira BioSciences' Growth Prospects
Oct 20Pacira BioSciences guides Q3 revenue below consensus
Oct 13Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures
Sep 27EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids
Sep 20Pacira BioSciences records 17.7% sequential growth in August revenue
Sep 13Pacira BioSciences provides update on July product sales
Aug 10Pacira BioSciences Q2 2022 Earnings Preview
Aug 02Pacira BioSciences sees Q2 revenue below consensus
Jul 14Shareholder Returns
| PCRX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.3% | 1.3% | 0.6% |
| 1Y | -41.8% | 7.9% | 23.7% |
Return vs Industry: PCRX underperformed the US Pharmaceuticals industry which returned 7.9% over the past year.
Return vs Market: PCRX underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| PCRX volatility | |
|---|---|
| PCRX Average Weekly Movement | 6.6% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PCRX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PCRX's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 712 | Frank Lee | www.pacira.com |
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product.
Pacira BioSciences, Inc. Fundamentals Summary
| PCRX fundamental statistics | |
|---|---|
| Market cap | US$907.30m |
| Earnings (TTM) | -US$90.73m |
| Revenue (TTM) | US$694.96m |
1.3x
P/S Ratio-10.0x
P/E RatioIs PCRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PCRX income statement (TTM) | |
|---|---|
| Revenue | US$694.96m |
| Cost of Revenue | US$255.38m |
| Gross Profit | US$439.58m |
| Other Expenses | US$530.31m |
| Earnings | -US$90.73m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 63.25% |
| Net Profit Margin | -13.06% |
| Debt/Equity Ratio | 78.4% |
How did PCRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 21:58 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pacira BioSciences, Inc. is covered by 34 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Richard Silver | Barclays |
| Balaji Prasad | Barclays |
| Anita Dushyanth | Berenberg |